|Bid||1,052.50 x 0|
|Ask||1,052.50 x 0|
|Day's Range||1,035.50 - 1,053.00|
|52 Week Range||985.00 - 1,379.60|
|Beta (5Y Monthly)||0.43|
|PE Ratio (TTM)||28.37|
|Earnings Date||Jul 28, 2022|
|Forward Dividend & Yield||0.30 (2.90%)|
|Ex-Dividend Date||Sep 29, 2022|
|1y Target Est||14.73|
Pharmaceutical firm GSK hired the finance chief of British luxury fashion group Burberry to lead its finances after the recent spinoff of its consumer-health business.
Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces the first cases for revision knee replacement utilizing its CORI◊ Surgical System. Dr. Thorsten Seyler of Duke University performed the first cases on August 17, 2022, combining Smith+Nephew's handheld robotics technology with its LEGION◊ Revision Knee System. Smith+Nephew is the first orthopaedics company to receive FDA 510(k) clearance for a revision indication using a robotics-assisted platform.
Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces it is expanding the reach of its medical education curriculum through a suite of advanced simulation technologies. Healthcare professionals can now conveniently access core orthopaedic, robotics and sports medicine procedural skills-training using virtual and augmented reality, haptics, and 3D interactive gaming at every Smith+Nephew Academy centre of excellence around the world.